The World Health Organization defines hormone replacement therapy as carcinogenic: Is this plausible?

References

• International Agency for Research on Cancer. IARC monographs programme finds combined estrogen–progestogen contraceptives and menopausal therapy are carcinogenic to humans. IARC, LyonFrance, Press release no. 167 [Internet] 2005 Jul 29 [cited 2007 Mar 6]. Available from: http://www.iarc.fr/ENG/Press_Releases/pr167a.html
   Google Scholar
• International Agency for Research on Cancer. Combined estrogen–progestogen menopausal therapy (Group 1). IARC, LyonFrance, Summary of data reported and evaluation. Monograph no. 2, section 5, 3rd draft, rev. 3 [Internet] undated [cited 2007 Mar 6]. Available from: http://monographs.iarc.fr/ENG/Meetings/91-menop-ther.pdf
   Google Scholar
• Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen–progestagen contraceptives and menopausal treatment. Lancet Oncol 2005; 6: 552–553
   PubMed Web of Science ®Google Scholar
• Schneider H PG, Mueck A O, Kuhl H. IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy. Climacteric 2005; 8: 311–316
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Monographs on the evaluation of the carcinogenic risks to humans: Supplement 7. IARC, LyonFrance 1987; 280–285
   Google Scholar
• International Agency for Research on Cancer. Monographs on the evaluation of the carcinogenic risks to humans, vol. 72: Hormonal contraception and postmenopausal hormone therapy. IARC, LyonFrance 1999; 474–530
   Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–1727
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–1059
   PubMed Web of Science ®Google Scholar
• Longman S M, Buehring G C. Oral contraceptives and breast cancer. In vitro effect of contraceptive steroids on human mammary cell growth. Cancer 1987; 59: 281–287
   PubMed Web of Science ®Google Scholar
• Seeger H, Lippert C, Wallwiener D, Lippert T H. Comparison of the effect of 17α-ethinylestradiol and 17β-estradiol on the proliferation of human breast cancer cells and human umbilical vascular endothelial cells. Clin Exp Obstet Gynecol 2002; 29: 87–90
   PubMedGoogle Scholar
• Anderson T J, Battersby S, King R J, McPherson K, Going J J. Oral contraceptive use influences resting breast proliferation. Human Pathol 1989; 20: 1139–1144
   PubMed Web of Science ®Google Scholar
• Brosens I A, Pijnenborg R. Comparative study of the estrogenic effect of ethinylestradiol and mestranol on the endometrium. Contraception 1976; 14: 679–685
   PubMed Web of Science ®Google Scholar
• Henderson B E, Feigelson H S. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427–433
   PubMed Web of Science ®Google Scholar
• Lang R, Reimann R. Studies for a genotoxic potential of some endogenous and exogenous sex steroids. Environ Mol Mutagen 1993; 21: 272–304
   PubMed Web of Science ®Google Scholar
• Seibert B, Günzel P. Animal toxicity studies performed for risk assessment on the once-a-month injectable contraceptive Mesigyna. Contraception 1994; 49: 303–333
   PubMed Web of Science ®Google Scholar
• Hundal B S, Dhillon V S, Sidhu I S. Genotoxic potential of estrogens. Mutat Res 1997; 389: 173–181
   PubMed Web of Science ®Google Scholar
• Dietel M, Lewis M A, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Human Reprod 2005; 20: 2052–2060
   PubMed Web of Science ®Google Scholar
• Liehr J G. Is estradiol a genotoxic mutagenic carcinogen?. Endocr Rev 2000; 21: 40–54
   PubMed Web of Science ®Google Scholar
• Russo J, Russo I H. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006; 102: 89–96
   PubMed Web of Science ®Google Scholar
• Mooberry S L. Mechanism of action of 2-methoxyestradiol: new developments. Drug Res Updates 2003; 6: 355–361
   PubMedGoogle Scholar
• Liehr J G. Modulation of estrogen-induced carcinogenesis by chemical modifications. Arch Toxicol 1984; 55: 119–122
   PubMed Web of Science ®Google Scholar
• Nielsen M, Thomsen J L, Primdahl S, Dyreborg U, Andersen J A. Breast cancer and atypia among young and middle-aged women: a study of 110 medico-legal autopsies. Br J Cancer 1987; 56: 814–819
   PubMed Web of Science ®Google Scholar
• WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 2003; 289: 3243–3253
   PubMed Web of Science ®Google Scholar
• Kuhl H. Is the elevated breast cancer risk observed in the WHI study an artefact?. Climacteric 2004; 7: 319–323
   PubMed Web of Science ®Google Scholar
• Naftolin F, Schneider H PG, Sturdee D W, for the Writing Group of the IMS Executive Committee, with contributions from the other members of the Executive Committee. Guidelines for hormone treatment of women in the menopausal transition and beyond. Position Statement by the Executive Committee of the International Menopause Society (revised October 15, 2004). Climacteric 2004; 7: 333–337
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006; 108: 1354–1360
   PubMed Web of Science ®Google Scholar
• Ravdin P M, Cronin K A, Howlader N, Berg C D, Chlebowski R T, Feuer E J, Edwards B K, Berry D A. The decrease in breast-cancer incidence in 2003 in the United States. New Engl J Med 2007; 356: 1670–1674
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe 2006. Ann Oncol 2007; 18: 581–592
   PubMed Web of Science ®Google Scholar
• Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304–315
   PubMed Web of Science ®Google Scholar
• Pike M C, Peters R K, Cozen W, Probst-Hensch N M, Felix J C, Wan P C, Mack T M. Estrogen–progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89: 1110–1116
   PubMed Web of Science ®Google Scholar
• Hill D A, Weiss N S, Beresford S A, Voigt L F, Daling J R, Stanford J L, Self S. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000; 183: 1456–1461
   PubMed Web of Science ®Google Scholar
• Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543–1551
   PubMed Web of Science ®Google Scholar
• Birkhauser M, Barlow D H, Notelovitz M, Rees M. Health plan for the adult woman. Management handbook. Taylor & Francis, London/New York 2005
   Google Scholar